Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 8/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14003392 | 0.89 | ALDH1A1 (0.41) | MAPTCNR1ALDH1A1P2RX3USP2 | |
| SCHEMBL4835537 | 0.77 | KDM4E (0.49) | MAPTCNR1CYP2C9CYP3A4NPC1 | |
| SCHEMBL14003395 | 0.77 | CNR1 (0.42) | MAPTCNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14003389 | 0.76 | CNR1 (0.48) | MAPTCNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4838849 | 0.73 | CNR1 (0.44) | MAPTCNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4832075 | 0.72 | CNR1 (0.55) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14003401 | 0.71 | CNR1 (0.41) | CNR1CYP2C9CYP2C19CYP3A4LMNA | |
| SCHEMBL4840650 | 0.71 | CNR1 (0.42) | MAPTCNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4841505 | 0.71 | CNR1 (0.41) | MAPTCNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5815578 | 0.70 | CNR1 (0.36) | CNR1CYP2C9CYP2C19CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2006138734-A1 | TRIAZOLOPYRIMIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | CNR1, CNR2, GPR68 | MAPT 2322/4885CNR1 1/4885CYP2C9 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.